Home Current Archive Editorial Team
About us
Aims and scope About Author Guidelines
News Contact
×
Home Current Archive Editorial board

Aims and scope About Author Guidelines
News Contact
Review paper
Received: 07.07.2021. >> Accepted: 15.09.2021. >> Published: 01.02.2022. Biochemistry
<< Prev | Next >>
PDF
https://doi.org/10.17392/1414-21

Revealing the decrease of indoleamine 2,3-dioxygenase as a major constituent for B cells survival post-mesenchymal stem cells co-cultured with peripheral blood mononuclear cell (PBMC) of systemic lupus erythematosus (SLE) patients

By
Dewi Masyithah Darlan Orcid logo ,
Dewi Masyithah Darlan
Contact Dewi Masyithah Darlan

Department of Parasitology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

Pusat Unggulan Tissue Engineering, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

View authors publications

Search this author on:

PubMed | Google Scholar
Delfitri Munir ,
Delfitri Munir

Pusat Unggulan Tissue Engineering, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

View authors publications

Search this author on:

PubMed | Google Scholar
Agung Putra ,
Agung Putra

Stem Cell and Cancer Research (SCCR), Sultan Agung Islamic University (UNISSULA), Semarang, Indonesia

Department of Postgraduate Biomedical Science, Medical Faculty, Sultan Agung Islamic University (UNISSULA), Semarang, Indonesia

Department of Pathological Anatomy, Medical Faculty, Sultan Agung Islamic University (UNISSULA), Semarang, Indonesia

View authors publications

Search this author on:

PubMed | Google Scholar
Iffan Alif ,
Iffan Alif

Stem Cell and Cancer Research (SCCR), Medical Faculty, Sultan Agung Islamic University (UNISSULA), Semarang, Indonesia

View authors publications

Search this author on:

PubMed | Google Scholar
Nur Dina Amalina ,
Nur Dina Amalina

Stem Cell and Cancer Research (SCCR), Medical Faculty, Sultan Agung Islamic University (UNISSULA), Semarang, Indonesia

Pharmacy Study Program, Faculty of Mathematics and Natural Science, Universitas Negeri Semarang, Semarang, Indonesia

View authors publications

Search this author on:

PubMed | Google Scholar
Nelva Karmila Jusuf ,
Nelva Karmila Jusuf

Department of Dermatology and Venereology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

View authors publications

Search this author on:

PubMed | Google Scholar
Imam Budi Putra
Imam Budi Putra

Department of Dermatology and Venereology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Medan, Indonesia

View authors publications

Search this author on:

PubMed | Google Scholar

Abstract

Aim
Mesenchymal stem cells (MSCs) have potent immunosuppressive properties to control systemic lupus erythematosus (SLE) disease by inhibiting indoleamine 2,3-dioxygenase (IDO), and increasing regulatory T cells (Treg) to control innate and adaptive immune cells. However, the interaction and mechanism regarding IDO and B cells in the co-culture of MSC and SLE peripheral blood mononuclear cell (PBMCs) remain unclear. This study aimed to investigate the effects of MSCs in controlling B cells through IDO expression in PBMC of SLE patients.
Methods
This study used a post-test control group design. MSCs were obtained from human umbilical cord blood and characterized according to their surface antigen expression and multilineage differentiation capacities. PBMCs isolated from SLE patients were divided into five groups: sham, control, and three treatment groups. The treatment groups were treated by co-culturing MSCs to PBMCs with a ratio of 1:10, 1:25, and 1:40 for 72 h incubation. The B cell levels were analysed by flow cytometry with cytometric bead array (CBA) and the IDO levels were determined by ELISA.
Results
The percentages of B cells decreased significantly in groups treated by dose-dependent MSCs, particularly in T1 and T2
groups. These findings were aligned with the significant decrease of the IDO level.
Conclusion
MSCs control B cells-mediated by a decrease of IDO in PBMC of SLE patients.

Keywords:

autoimmune disease,
immunoregulation,
inflammatory disorder

References

1.
Yaniv G, Twig G, Shor D, Furer A, Sherer Y, Mozes O, et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev. 2015. p. 75–9.
2.
Malkiel S, Barlev A, Atisha-Fregoso Y, Suurmond J, Diamond B. Plasma cell differentiation pathways in systemic lupus erythematosus. Front Immunol. 2018. p. 427.
3.
Yap D, Chan T. B cell abnormalities in systemic lupus erythematosus and lupus nephritis-role in pathogenesis and effect of immunosuppressive treatments. Int J Mol Sci. 2019. p. 1–18.
4.
Prechl J. A generalized quantitative antibody homeostasis model: Antigen saturation, natural antibodies and a quantitative antibody network. Clin Transl Immunol. 2017. p. 131–7.
5.
Barbado J, Tabera S, Sánchez A, García-Sancho J. Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis. Lupus. 2018. p. 2161–5.
6.
Putra A, Ridwan F, Putridewi A, Kustiyah A, Wirastuti K, Sadyah N, et al. The role of tnf-α induced mscs on suppressive inflammation by increasing tgf-β and il-10. Open Access Maced. J Med Sci. 2018. p. 1779–83.
7.
Hamra N, Putra A, Tjipta A, Amalina N, Nasihun T. Hypoxia mesenchymal stem cells accelerate wound closure improvement by controlling α-smooth muscle actin expression in the full-thickness animal model. Open Access Maced J Med Sci. 2021. p. 35–41.
8.
Das M, Sundell I, Koka P. Adult mesenchymal stem cells and their potency in the cell-based therapy. J Stem Cells. 2013. p. 1–16.
9.
Asari S, Itakura S, Ferreri K, Liu C, Kuroda Y, Kandeel F, et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol. 2009. p. 604–15.
10.
Croitoru-Lamoury J, Lamoury F, Caristo M, Suzuki K, Walker D, Takikawa O, et al. Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One. 2011. p. 14698.
11.
FUNDING No specific funding was received for this study. TRANSPARENCY DECLARATION Competing interests: None to declare.
12.
Fan L, Hu C, Chen J, Cen P, Wang J, Li L. Interaction between mesenchymal stem cells and B-cells. Int J Mol Sci. 2016. p. 650.
13.
Darlan D, Munir D, Putra A, Jusuf N. MSCsreleased TGFβ1 generate CD4+CD25+Foxp3+ in T-reg cells of human SLE PBMC. J Formos Med Assoc. 2020. p. 1–7.
14.
Munir D, Lubis R, Darlan D, Putra A, Alif I. The role of mesenchymal stem cells in decreasing interleukin-12 human systemic lupus erythematosus. Open Access Maced J Med Sci. 2020. p. 787–92.
15.
Baghaei K, Hashemi S, Tokhanbigli S, Rad A, Assadzadeh-Aghdaei A, Sharifian H, et al. Isolation, differentiation, and characterization of mesenchymal stem cells from human bone marrow. Gastroenterol Hepatol Bed Bench. 2017. p. 208–13.
16.
Iikuni N, Lourenço E, V, Hahn B, Cava L, A. Cutting Edge: Regulatory T cells directly suppress B Cells in systemic lupus erythematosus. J Immunol. 2009. p. 1518–22.
17.
Taher T, Bystrom J, Ong V, Isenberg D, Renaudineau Y, Abraham D, et al. Intracellular B lymphocyte signalling and the regulation of humoral immunity and autoimmunity. Clin Rev Allergy Immunol. 2017. p. 237–64.
18.
Sørensen R, Hadrup S, Svane I, Hjortsø M, Straten T, Andersen P, et al. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood. 2011. p. 2200–10.
19.
Godin-Ethier J, Hanafi L, Duvignaud J, Leclerc D, Lapointe R. IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive. Mol Immunol. 2011. p. 253–9.
20.
Lim J, Kim B, Ryu D Bin, Kim T, Park G, Min C. The therapeutic efficacy of mesenchymal stromal cells on experimental colitis was improved by the IFN-γ and poly(I:C) priming through promoting the expression of indoleamine 2,3-dioxygenase. Stem Cell Res Ther. 2021. p. 1–13.
21.
Darlan D, Munir D, Jusuf K, Putra N, Ikhsan A, Alif R, et al. In vitro regulation of IL-6 and TGF-ß by mesenchymal stem cells in systemic lupus erythematosus patients. Med Glas (Zenica). 2020. p. 408–13.

Citation

Copyright

Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

 

Article metrics

Google scholar: See link

{{ submission.title }}
Issue image
Vol 19, Issue 1, 2022
Revealing the decrease of indoleamine 2,3-dioxygenase as a major constituent for B cells survival post-mesenchymal stem cells co-cultured with peripheral blood mononuclear cell (PBMC) of systemic lupus erythematosus (SLE) patients Rats’ umbilical-cord mesenchymal stem cells ameliorate mast cells and Hsp70 on ovalbumin-induced allergic rhinitis rats The effect of the shape of a clip on the magnetic field during magnetic resonance imaging examinations Pregnancy outcomes of COVID-19 positive pregnant women at the Cantonal Hospital Zenica, Bosnia and Herzegovina Relationship between depression and quality of life after myocardial infarction See full issue

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.